Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Virtual Reality Exercise Alleviates Postprandial Vascular and Metabolic Impairment in Adolescents With Congenital Heart Disease: A Randomized Controlled Crossover Trial.

Korean circulation journal·2026

Same author

Attenuated peripheral vascular responsiveness contributes to baroreflex dysfunction in patients with wild-type transthyretin amyloidosis.

American journal of physiology. Heart and circulatory physiology·2026

Same author

The association between extracellular fluid volume and sympathetic nervous system activity in patients with chronic kidney disease.

American journal of physiology. Renal physiology·2025

Same author

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: <i>Treatment Patterns and Risk Trajectories</i>.

Pulmonary circulation·2025

Same author

Beyond the QT interval: how QT/RR hysteresis may reveal a sex-dependent hidden risk for cardiac arrhythmias.

American journal of physiology. Heart and circulatory physiology·2025

Same author

The influence of biological sex on the metabolic basis of skeletal muscle fatigue in vivo.

The Journal of physiology·2025

Search research articles

Related Experiment Video

Updated: Jul 2, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Statin administration improves vascular function in heart failure with preserved ejection fraction.

Jarred J Iacovelli¹, Jeremy K Alpenglow¹, Stephen M Ratchford²

¹Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, United States.

Journal of Applied Physiology (Bethesda, Md. : 1985)

|February 22, 2024

Summary

Low-dose atorvastatin improved vascular endothelial function in patients with heart failure with preserved ejection fraction (HFpEF). This statin therapy enhanced brachial artery vasodilation and reduced oxidative stress markers in HFpEF patients.

Keywords:

blood flow flow-mediated dilation heart failure reactive hyperemia statin

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Jul 2, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Area of Science:

Cardiology
Vascular Medicine
Pharmacology

Background:

Heart failure with preserved ejection fraction (HFpEF) is associated with impaired vascular endothelial function.
Hydroxy-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) may improve vascular function.

Purpose of the Study:

To evaluate the efficacy of 30-day atorvastatin administration on peripheral vascular function and biomarkers of inflammation and oxidative stress in patients with HFpEF.

Main Methods:

A parallel, double-blind, placebo-controlled study involving 16 HFpEF patients (8 statin, 8 placebo).
Assessed flow-mediated dilation (FMD), sustained-stimulus FMD (SS-FMD), reactive hyperemia (RH), and exercise hyperemia.
Measured malondialdehyde (MDA) as a marker of lipid peroxidation.

Main Results:

Atorvastatin significantly improved FMD and SS-FMD, indicating enhanced conduit and microvascular function.
RH and exercise hyperemia remained unchanged in both groups.
Statin administration reduced MDA levels, a marker of oxidative damage.

Conclusions:

Low-dose atorvastatin improves brachial artery endothelium-dependent vasodilation in HFpEF patients.
The benefits may be partly attributed to reductions in oxidative stress.
Statin therapy did not improve microvascular reactivity or exercising muscle blood flow in this cohort.